A profile of multiple sclerosis: The New York State Multiple Sclerosis Consortium

被引:46
作者
Jacobs, LD
Wende, KE
Brownscheidle, CM
Apatoff, B
Coyle, PK
Goodman, A
Gottesman, MH
Granger, CV
Greenberg, SJ
Herbert, J
Krupp, L
Lava, NS
Mihai, C
Miller, AE
Perel, A
Smith, CR
Snyder, DH
机构
[1] Buffalo Gen Hosp, Dept Neurol, Buffalo, NY 14203 USA
[2] Cornell Univ, Med Ctr, Dept Neurol & Neurosci, New York, NY 10021 USA
[3] SUNY Stony Brook, Univ Hosp, Dept Neurol, Stony Brook, NY 11794 USA
[4] Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA
[5] Winthrop Univ Hosp, Div Neurol, Mineola, NY 11501 USA
[6] SUNY Buffalo, Ctr Funct Assessment Res, Dept Rehabil Med, Buffalo, NY 14214 USA
[7] Roswell Pk Canc Inst, Baird MS & Neuroimmunol Tissue Repository, Buffalo, NY 14263 USA
[8] Hosp Joint Dis & Med Ctr, Inst Orthopaed, MS Care Ctr, New York, NY 10003 USA
[9] Albany Med Coll, Dept Neurol, Albany, NY 12208 USA
[10] SUNY Hlth Sci Ctr, Dept Neurol, Syracuse, NY 13210 USA
[11] Maimonides Hosp, Div Neurol, Brooklyn, NY 11219 USA
[12] Staten Isl Univ Hosp, MS Ctr, Staten Isl, NY 10306 USA
[13] St Agnes Hosp, MS Ctr, White Plains, NY 10605 USA
[14] New York Hosp, Queens Med Ctr, Flushing, NY 11355 USA
关键词
multiple sclerosis; demyelinating disease; neurodegenerative disease;
D O I
10.1177/135245859900500511
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
We have obtained a current Profile of multiple sclerosis (MS) in New York State through a centralized patient registry and standardized data collection instrument associated with the New York Stale Multiple Sclerosis Consortium of 12 MS centers located throughout the state. Data from the first 3019 Patients with clinically definite MS revealed a clear relationship between MS disease type, duration of disease, and severity of physical disability Patients with relapsing disease had disease durations approximately half as long as those with progressive forms of the disease (means approximately 6 years versus 11 years). The majority of patients with relapsing disease had Expanded Disability Status Scale (EDSS) scores of 4.0 or less (self-sustained, fully ambulatory), whereas the majority of patients with progressive disease types had EDSS scores of 6.0 or greater (at least unilateral assist for walking). These findings emphasize the importance of early intervention in Patients with relapsing disease to slow or prevent the accumulation of Physical disability associated with Progressive types of disease. Progressive disease was associated with lock of full-time employment and being disabled before the age of 60 years. Patients with relapsing disease were more likely to be employed and have private forms of insurance, whereas patients with progressive types of disease were more likely to have government-supported insurance to cover medical expenses.
引用
收藏
页码:369 / 376
页数:8
相关论文
共 26 条
[1]  
[Anonymous], 1993, Multiple Sclerosis: a statistical portrait
[2]   INTERFERON BETA-1B IS EFFECTIVE IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS - CLINICAL-RESULTS OF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].
DUQUETTE, P ;
GIRARD, M ;
DESPAULT, L ;
DUBOIS, R ;
KNOBLER, RL ;
LUBLIN, FD ;
KELLEY, L ;
FRANCIS, GS ;
LAPIERRE, Y ;
ANTEL, J ;
FREEDMAN, M ;
HUM, S ;
GREENSTEIN, JI ;
MISHRA, B ;
MULDOON, J ;
WHITAKER, JN ;
EVANS, BK ;
LAYTON, B ;
SIBLEY, WA ;
LAGUNA, J ;
KRIKAWA, J ;
PATY, DW ;
OGER, JJ ;
KASTRUKOFF, LF ;
MOORE, GRW ;
HASHIMOTO, SA ;
MORRISON, W ;
NELSON, J ;
GOODIN, DS ;
MASSA, SM ;
GUTTERIDGE, E ;
ARNASON, BGW ;
NORONHA, A ;
REDER, AT ;
MARTIA, R ;
EBERS, GC ;
RICE, GPA ;
LESAUX, J ;
JOHNSON, KP ;
PANITCH, HS ;
BEVER, CT ;
CONWAY, K ;
WALLENBERG, JC ;
BEDELL, L ;
VANDENNOORT, S ;
WEINSHENKER, B ;
WEISS, W ;
REINGOLD, S ;
PACHNER, A ;
TAYLOR, W .
NEUROLOGY, 1993, 43 (04) :655-661
[3]  
EBERS GC, 1998, MULT SCLER, P192
[4]  
EBERS GC, 1998, MULT SCLER, P5
[5]   EPIDEMIOLOGIC ASPECTS OF HASHIMOTOS THYROIDITIS AND GRAVES-DISEASE IN ROCHESTER, MINNESOTA (1935-1967), WITH SPECIAL REFERENCE TO TEMPORAL TRENDS [J].
FURSZYFE.J ;
WOOLNER, LB ;
MCCONAHE.WM ;
ELVEBACK, LR ;
KURLAND, LT .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1972, 21 (03) :197-+
[6]  
Goodkin DE, 1992, TREATMENT MULTIPLE S, P17
[7]   Intramuscular interferon beta-1 alpha for disease progression in relapsing multiple sclerosis [J].
Jacobs, LD ;
Cookfair, DL ;
Rudick, RA ;
Herndon, RM ;
Richert, JR ;
Salazar, AM ;
Fischer, JS ;
Goodkin, DE ;
Granger, CV ;
Simon, JH ;
Alam, JJ ;
Bartoszak, DM ;
Bourdette, DN ;
Braiman, J ;
Brownscheidle, CM ;
Coats, ME ;
Cohan, SL ;
Dougherty, DS ;
Kinkel, RP ;
Mass, MK ;
Munschauer, FE ;
Priore, RL ;
Pullicino, PM ;
Scherokman, BJ ;
WeinstockGuttman, B ;
Whitman, RH ;
Baird, WC ;
Fillmore, M ;
Bona, LM ;
ColonRuiz, ME ;
Nadine, BS ;
Donovan, A ;
Bennett, S ;
Kieffer, YM ;
Umhauer, MA ;
Miller, CE ;
Kilic, AK ;
Sargent, EL ;
Schachter, M ;
Shucard, DW ;
Weider, V ;
Catalano, BA ;
Cervi, JM ;
Czekay, C ;
Farrell, JL ;
Filippini, JS ;
Matyas, RC ;
Michienzi, KE ;
Ito, M ;
OMalley, JA .
ANNALS OF NEUROLOGY, 1996, 39 (03) :285-294
[8]   Epidemiology and estimated population burden of selected autoimmune diseases in the United States [J].
Jacobson, DL ;
Gange, SJ ;
Rose, NR ;
Graham, NMH .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1997, 84 (03) :223-243
[9]   COPOLYMER-1 REDUCES RELAPSE RATE AND IMPROVES DISABILITY IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS - RESULTS OF A PHASE-III MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].
JOHNSON, KP ;
BROOKS, BR ;
COHEN, JA ;
FORD, CC ;
GOLDSTEIN, J ;
LISAK, RP ;
MYERS, LW ;
PANITCH, HS ;
ROSE, JW ;
SCHIFFER, RB ;
VOLLMER, T ;
WEINER, LP ;
WOLINSKY, JS ;
BIRD, SJ ;
CONSTANTINESCU, C ;
KOLSON, DL ;
GONZALEZSCARANO, F ;
BRENNAN, D ;
PFOHL, D ;
MANDLER, RN ;
ROSENBERG, GA ;
JEFFREY, C ;
BARGER, GR ;
GANDHI, B ;
MOORE, PM ;
ROGERS, LR ;
LISAK, D ;
SMITH, L ;
ELLISON, GW ;
BAUMHEFNER, RW ;
CRAIG, SL ;
JALBUT, SS ;
KATZ, E ;
CONWAY, KL ;
BURNS, JB ;
SHIBA, C ;
GIANG, DW ;
PETRIE, MD ;
GUARNACCIA, JB ;
ANDERSON, S ;
MCKEON, A ;
MCCARTHY, M ;
THOMAS, AB ;
VRIESENDORP, FJ ;
AUSTIN, SG ;
LINDSEY, JW ;
DIMACHKIE, M ;
CERRETA, E ;
KACHUCK, N ;
MCCARTHY, KA .
NEUROLOGY, 1995, 45 (07) :1268-1276
[10]   STUDIES ON NATURAL-HISTORY OF MULTIPLE-SCLEROSIS .8. EARLY PROGNOSTIC FEATURES OF LATER COURSE OF ILLNESS [J].
KURTZKE, JF ;
BEEBE, GW ;
NAGLER, B ;
KURLAND, LT ;
AUTH, TL .
JOURNAL OF CHRONIC DISEASES, 1977, 30 (12) :819-830